Leerink Partnrs Brokers Decrease Earnings Estimates for Genmab A/S (NASDAQ:GMAB)

Genmab A/S (NASDAQ:GMAB) – Equities researchers at Leerink Partnrs cut their FY2025 EPS estimates for shares of Genmab A/S in a research note issued to investors on Thursday, August 8th. Leerink Partnrs analyst J. Chang now forecasts that the company will earn $1.53 per share for the year, down from their previous forecast of $1.56. The consensus estimate for Genmab A/S’s current full-year earnings is $1.13 per share.

Other equities research analysts also recently issued research reports about the stock. BTIG Research boosted their price objective on shares of Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a research report on Thursday, June 27th. Royal Bank of Canada raised Genmab A/S from a “sector perform” rating to an “outperform” rating in a report on Monday, July 15th. Truist Financial raised their price objective on Genmab A/S from $50.00 to $53.00 and gave the stock a “buy” rating in a research note on Tuesday, June 4th. Finally, HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Genmab A/S in a research note on Friday, August 9th. Three equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, Genmab A/S presently has an average rating of “Hold” and a consensus target price of $49.50.

Genmab A/S Trading Up 0.2 %

Shares of NASDAQ GMAB opened at $26.57 on Monday. Genmab A/S has a 12-month low of $24.53 and a 12-month high of $39.53. The firm has a market capitalization of $17.57 billion, a price-to-earnings ratio of 22.14, a price-to-earnings-growth ratio of 1.01 and a beta of 0.97. The firm has a 50 day moving average of $26.71 and a 200 day moving average of $28.20.

Institutional Trading of Genmab A/S

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Benjamin F. Edwards & Company Inc. grew its holdings in Genmab A/S by 7.1% during the 2nd quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after buying an additional 478 shares in the last quarter. Renaissance Technologies LLC boosted its position in shares of Genmab A/S by 7.6% during the second quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after acquiring an additional 103,859 shares during the last quarter. Oppenheimer Asset Management Inc. grew its stake in Genmab A/S by 26.3% during the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock valued at $5,480,000 after acquiring an additional 45,376 shares in the last quarter. Headlands Technologies LLC increased its holdings in Genmab A/S by 1,702.8% in the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after acquiring an additional 4,853 shares during the last quarter. Finally, Choreo LLC purchased a new stake in Genmab A/S in the 2nd quarter worth $776,000. Institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.